Galapagos selected for BEL 20 Index

Mechelen, Belgium; 7 March 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) announces that Euronext has selected Galapagos NV for inclusion in the BEL 20^® Index on Euronext Brussels, effective 21 March 2016.

The BEL 20 represents the 20 largest companies traded on Euronext Brussels, subject to meeting Euronext Index Family criteria and review.  For a complete overview of criteria and index rules, please see The Index Family Rulebook, at www.euronext.com.

"We are proud that in our 11^th year as a listed company on Euronext, and our 17^th year since we were incorporated in 1999, we are now included in the BEL 20, the prestigious index of largest public companies in Belgium.  It shows the growth of Galapagos from a biotech start-up to an integrated discovery and development company that is bringing innovative new medicines to patients," says Onno van de Stolpe, CEO and Founder.

About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.  Our pipeline comprises three Phase 2, three Phase 1, five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications.  We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world.  Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives.  The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 440 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  More information at www.glpg.com.

CONTACT

Investors:                                                    Media:
Elizabeth Goodwin                                           Evelyn Fox
VP IR & Corporate Communications                  Director Communications
+1 781 460 1784                                            +31 6 53 591 999
ir@glpg.com                                                   communications@glpg.com

Forward-Looking Statements
This release may contain forward-looking statements, including statements.  Galapagos cautions the reader that forward-looking statements are not guarantees of future performance.  Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements.  In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.  A list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' prospectus filed with the SEC on 14 May 2015 and subsequent filings and reports filed by Galapagos with the SEC.  Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.  These forward-looking statements speak only as of the date of publication of this document.  Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.